Integrating aetiologic testing for Chlamydia trachomatis and Neisseria gonorrhoeae using GeneXpert

Integrating aetiologic testing for Chlamydia trachomatis and Neisseria gonorrhoeae using GeneXpert® and treatment of sexually transmitted infections into primary health care services: a pilot study.

Rationale

Mathematical modeling indicates that implementing STI screening and treatment can greatly impact the overall incidence of STIs in a population. Focusing on screening through GeneXpert-like tests in South Africa, particularly among youth aged 15-24 and those in HIV care, could result in substantial reductions in both the incidence and prevalence of bacterial STIs over a decade, even with modest coverage rates. It’s noteworthy that individuals starting PrEP are at significantly higher risk, with rates of STIs potentially up to 10 times greater than the general population.

South Africa stands out as a potential leader in offering GeneXpert®-based STI screening, given the platform’s introduction in 2011 as part of a rapid expansion of tuberculosis testing nationwide. GeneXpert® machines are already in place within the South African National Health Laboratory Service (NHLS) facilities throughout the country. Presently, the Xpert® CT/NG® assay from Cepheid in Sunnyvale, CA, US, is the sole test that meets WHO’s REASSURED criteria for point-of-care (POC) testing. This assay delivers results in just 90 minutes using existing NHLS laboratory infrastructure.

NHLS is actively exploring the feasibility of expanding POC testing for specific medical conditions, further enhancing the accessibility and efficiency of diagnostic services.

Investigators

Prof Sinead Delany-Moretlwe

Dr Danielle Travill

Latest Update:

March 2024

For more about Integrating aetiologic testing for Chlamydia trachomatis and Neisseria gonorrhoeae using GeneXpert please email rhicomms@wrhi.ac.za